CS85991A3 - Polyfunctional pharmaceuticals - Google Patents

Polyfunctional pharmaceuticals Download PDF

Info

Publication number
CS85991A3
CS85991A3 CS91859A CS85991A CS85991A3 CS 85991 A3 CS85991 A3 CS 85991A3 CS 91859 A CS91859 A CS 91859A CS 85991 A CS85991 A CS 85991A CS 85991 A3 CS85991 A3 CS 85991A3
Authority
CS
Czechoslovakia
Prior art keywords
oxo
dihydro
purin
ait
solution
Prior art date
Application number
CS91859A
Other languages
Czech (cs)
English (en)
Inventor
Alvin J Glasky
Original Assignee
Alvin J Glasky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alvin J Glasky filed Critical Alvin J Glasky
Publication of CS85991A3 publication Critical patent/CS85991A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
CS91859A 1990-03-28 1991-03-28 Polyfunctional pharmaceuticals CS85991A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/500,789 US5091432A (en) 1990-03-28 1990-03-28 9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use

Publications (1)

Publication Number Publication Date
CS85991A3 true CS85991A3 (en) 1992-02-19

Family

ID=23990941

Family Applications (1)

Application Number Title Priority Date Filing Date
CS91859A CS85991A3 (en) 1990-03-28 1991-03-28 Polyfunctional pharmaceuticals

Country Status (17)

Country Link
US (1) US5091432A (fr)
EP (1) EP0522082B1 (fr)
JP (1) JP3198335B2 (fr)
KR (1) KR100194162B1 (fr)
AT (1) ATE154880T1 (fr)
AU (1) AU7678191A (fr)
CA (1) CA2079342C (fr)
CS (1) CS85991A3 (fr)
DE (1) DE69126701T2 (fr)
DK (1) DK0522082T3 (fr)
ES (1) ES2104700T3 (fr)
GR (1) GR3024904T3 (fr)
IE (1) IE81123B1 (fr)
IL (1) IL97638A (fr)
NZ (1) NZ237574A (fr)
TW (1) TW279865B (fr)
WO (1) WO1991014434A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6338963B1 (en) * 1994-07-25 2002-01-15 Neotherapeutics, Inc. Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
US5801184A (en) * 1994-07-25 1998-09-01 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
WO1996003125A1 (fr) 1994-07-25 1996-02-08 Glasky Alvin J Modificateurs du guanylyle dependants du monoxyde de carbone
US5447939A (en) * 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
US6303617B1 (en) * 1998-05-04 2001-10-16 Neotherapeutics, Inc. Serotonin-like 9-substituted hypoxanthine and methods of use
AU3879899A (en) * 1998-05-04 1999-11-23 Neotherapeutics, Inc. Novel dopamine-like 9-substituted hypoxanthine and methods of use
US6297226B1 (en) 1999-10-15 2001-10-02 Neotherapeutics, Inc. Synthesis and methods of use of 9-substituted guanine derivatives
US6288069B1 (en) 1999-11-16 2001-09-11 Neotherapeutics, Inc. Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
JP3989247B2 (ja) * 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
US6407237B1 (en) 2001-02-21 2002-06-18 Neotherapeutics, Inc. Crystal forms of 9-substituted hypoxanthine derivatives
US6849735B1 (en) 2000-06-23 2005-02-01 Merck Eprova Ag Methods of synthesis for 9-substituted hypoxanthine derivatives
DK1790344T3 (da) 2000-07-07 2011-05-02 Spectrum Pharmaceuticals Inc Fremgangsmåder til behandling af sygdomsfremkaldt perifer neuropati og beslægtede tilstande
US20020040031A1 (en) * 2000-07-07 2002-04-04 Glasky Michelle S. Methods for prevention of accumulation of amyloid beta peptide in the central nervous system
US20020128264A1 (en) * 2000-07-07 2002-09-12 Taylor Eve M. Methods for treatment of conditions affected by activity of multidrug transporters
US20020040032A1 (en) * 2000-07-07 2002-04-04 Glasky Michelle S. Methods for stimulation of synthesis of synaptophysin in the central nervous system
US20020091133A1 (en) * 2000-12-12 2002-07-11 Eve M. Taylor Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis
US6759427B2 (en) * 2001-04-20 2004-07-06 Spectrum Pharmaceuticals, Inc. Synthesis and methods of use of tetrahydroindolone analogues and derivatives
US20020156277A1 (en) * 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
US20030055249A1 (en) * 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
US6906190B2 (en) * 2002-01-04 2005-06-14 Ribapharm Inc. Inhibitors for de novo-RNA polymerases and methods of identifying targets for same
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US7473728B2 (en) * 2004-12-16 2009-01-06 The Goodyear Tire & Rubber Company Dual phase rubber composition and tire with nanocomposite-containing sidewall thereof
CA2592320C (fr) 2004-12-22 2015-11-24 Neurochem (International) Limited Methodes et compositions de traitement de maladies liees a l'amyloide
US8372886B2 (en) * 2005-12-22 2013-02-12 Kiacta Sarl Treatment of renal disorders, diabetic nephropathy and dyslipidemias
PL3851447T3 (pl) 2006-10-12 2024-03-04 Bellus Health Inc. Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy
CA2673022A1 (fr) * 2006-12-22 2008-07-03 Bellus Health (International) Limited Procedes, composes et compositions permettant de traiter des troubles metaboliques et le diabete
ES2916805T3 (es) * 2012-11-21 2022-07-06 Zoetis Services Llc Síntesis de derivados de isoxazolina espirocíclicos
CN115521306B (zh) * 2022-09-26 2024-03-26 贵州大学 一种1,2,3,4-四氢-β-咔啉衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3321369A (en) * 1965-05-26 1967-05-23 Abbott Lab Method of enhancing learning rate and retention level in warm blooded animals
US3438968A (en) * 1966-06-23 1969-04-15 Int Chem & Nuclear Corp Substituted ammonium basic addition salts of ribonucleic acid
US4221910A (en) * 1978-09-15 1980-09-09 Newport Pharmaceuticals International, Inc. 9-(Hydroxy alkyl)purines
US4221909A (en) * 1978-09-15 1980-09-09 Sloan-Kettering Institute For Cancer Research P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines
US4221794A (en) * 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
IL64501A (en) * 1980-12-22 1985-07-31 Astra Laekemedel Ab 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use
US4728605A (en) * 1984-07-31 1988-03-01 Fudenberg Herman H Methods for recognizing and diagnosing subsets of Alzheimer's disease associated with immune system dysfunction, and for the in vitro testing of possible therapeutic agents for treatment of same
US4952693A (en) * 1984-10-12 1990-08-28 Warner-Lambert Company Oxazolo-pyrimidine derivatives

Also Published As

Publication number Publication date
EP0522082A1 (fr) 1993-01-13
CA2079342C (fr) 2001-10-23
CA2079342A1 (fr) 1991-09-29
IE910994A1 (en) 1991-10-09
TW279865B (fr) 1996-07-01
KR100194162B1 (ko) 1999-06-15
US5091432A (en) 1992-02-25
EP0522082A4 (en) 1993-06-09
DE69126701T2 (de) 1997-12-04
EP0522082B1 (fr) 1997-07-02
ATE154880T1 (de) 1997-07-15
IE81123B1 (en) 2000-03-22
JP3198335B2 (ja) 2001-08-13
AU7678191A (en) 1991-10-21
JPH05508390A (ja) 1993-11-25
DK0522082T3 (da) 1997-07-21
DE69126701D1 (de) 1997-08-07
IL97638A0 (en) 1992-06-21
NZ237574A (en) 1993-09-27
WO1991014434A1 (fr) 1991-10-03
IL97638A (en) 1999-03-12
ES2104700T3 (es) 1997-10-16
GR3024904T3 (en) 1998-01-30

Similar Documents

Publication Publication Date Title
CS85991A3 (en) Polyfunctional pharmaceuticals
DE60315615T2 (de) Tricyclische verbindungen basierend auf thiophen und arzneimittel, die diese umfassen
EP1768985B1 (fr) Derives de pyrimido-benzimidazole et leur utilisation comme agonistes ou antgonistes des récepteurs des mélanocortines
KR100667645B1 (ko) 환상 아민 ｃｃｒ3 길항제
EP1560582A2 (fr) DERIVES D'AZAINDOLE UTILISES EN TANT QU'INHIBITEURS DE LA KINASE p38
AU2006216713A1 (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
KR20020041456A (ko) 9-치환 구아닌 유도체의 합성 및 사용 방법
US20130338372A1 (en) Substituted Imidazoline Compounds
LT3671B (en) Substituted 1-(1h-imidazol-4-il)alkylbenzamides
JP2003503482A (ja) 環化アミノ酸誘導体
SK282766B6 (sk) Diazepinoindoly ako inhibítory fosfodiesterázy IV, ich použitie ako liečiv a farmaceutické kompozície s ich obsahom
JP2519734B2 (ja) 新規置換ピリド〔２，３−ｂ〕〔１，４〕ベンゾジアゼピン−６−オン，その製法及びその化合物を含む医薬
JPH05509314A (ja) 治療薬
RU2379305C2 (ru) Соединение тиоморфолина и способ его получения
JP2003503476A (ja) 環化アミド誘導体
WO2009064274A1 (fr) Composés d'imidazoazépinone énantiomériquement enrichis
US6583138B1 (en) Heterocyclic-ring condensed benzothiazine compound
US5114944A (en) 2-phenylpyrazolo[1,5-a]pyrimidine-3-acetic acid derivatives exhibiting therapeutic effects
US5057534A (en) 3-amino-5-arylpyrazole-4-acetic acid derivatives exhibiting therapeutic effects
CN116535390A (zh) pH敏感型4-酰胺哌啶类衍生物、药物组合物及其制备方法和应用
ITMI931897A1 (it) Derivati 1,3,4- benzotriazepin-5(4h)-one e procedimento per la loro preparazione
JPH0395166A (ja) イソキサゾロン誘導体含有脳機能改善剤
US20220332750A1 (en) Adenosine compound, its pharmaceutically acceptable salt or its stereoisomer and use thereof
NO318757B1 (no) 2-{4-[4-(4,5-diklor-2-metylimidazol-1-yl)butyl]-1-piperazinyl}-5-fluorpyrimidin, fremstilling og terapeutisk anvendelse
JPH01265070A (ja) カルバモイル−２−ピロリジノン化合物